Illumina Inc. (ILMN) Upgraded at Vetr Inc.
Vetr upgraded shares of Illumina Inc. (NASDAQ:ILMN) from a hold rating to a strong-buy rating in a research note issued to investors on Tuesday morning. They currently have $165.56 target price on the life sciences company’s stock.
Several other brokerages also recently weighed in on ILMN. JPMorgan Chase & Co. raised their price target on shares of Illumina from $185.00 to $200.00 and gave the company an overweight rating in a research report on Wednesday, July 27th. Cantor Fitzgerald reissued a hold rating and set a $165.00 price target on shares of Illumina in a research report on Wednesday, July 27th. Mizuho raised their price target on shares of Illumina from $138.00 to $148.00 and gave the company a neutral rating in a research report on Wednesday, July 27th. Citigroup Inc. downgraded shares of Illumina from a buy rating to a neutral rating and reduced their price target for the company from $190.00 to $140.00 in a research report on Tuesday. Finally, Zacks Investment Research raised shares of Illumina from a sell rating to a hold rating and set a $186.00 price target for the company in a research report on Thursday, July 28th. Two investment analysts have rated the stock with a sell rating, fifteen have given a hold rating, nine have issued a buy rating and one has given a strong buy rating to the company. Illumina has an average rating of Hold and a consensus target price of $156.88.
Illumina (NASDAQ:ILMN) opened at 137.17 on Tuesday. The firm has a market capitalization of $20.11 billion, a P/E ratio of 46.98 and a beta of 0.47. The firm’s 50-day moving average price is $172.04 and its 200 day moving average price is $156.15. Illumina has a one year low of $127.10 and a one year high of $196.47.
Illumina (NASDAQ:ILMN) last released its quarterly earnings results on Tuesday, July 26th. The life sciences company reported $0.86 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.73 by $0.13. Illumina had a net margin of 18.73% and a return on equity of 23.69%. The company earned $600 million during the quarter, compared to the consensus estimate of $31.91 million. During the same period in the prior year, the firm earned $0.80 earnings per share. Illumina’s revenue was up 11.3% on a year-over-year basis. On average, equities analysts anticipate that Illumina will post $3.53 earnings per share for the current fiscal year.
In other news, Director Daniel Bradbury sold 600 shares of the firm’s stock in a transaction dated Friday, October 7th. The shares were sold at an average price of $184.36, for a total value of $110,616.00. Following the transaction, the director now directly owns 17,065 shares of the company’s stock, valued at $3,146,103.40. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Robert S. Epstein sold 300 shares of the firm’s stock in a transaction dated Monday, August 22nd. The stock was sold at an average price of $170.27, for a total transaction of $51,081.00. Following the completion of the transaction, the director now directly owns 7,224 shares in the company, valued at $1,230,030.48. The disclosure for this sale can be found here. 1.60% of the stock is currently owned by insiders.
Several institutional investors have recently bought and sold shares of ILMN. Glenmede Trust Co. NA boosted its stake in Illumina by 26.2% in the first quarter. Glenmede Trust Co. NA now owns 3,660 shares of the life sciences company’s stock valued at $593,000 after buying an additional 760 shares during the last quarter. Virginia Retirement System purchased a new stake in Illumina during the first quarter valued at about $385,000. IFP Advisors Inc boosted its stake in Illumina by 215.6% in the first quarter. IFP Advisors Inc now owns 1,133 shares of the life sciences company’s stock valued at $184,000 after buying an additional 774 shares during the last quarter. NN Investment Partners Holdings N.V. purchased a new stake in Illumina during the first quarter valued at about $403,000. Finally, Menta Capital LLC purchased a new stake in Illumina during the first quarter valued at about $603,000. 95.22% of the stock is currently owned by hedge funds and other institutional investors.
Illumina Company Profile
Illumina, Inc (Illumina) offers sequencing and array-based solutions for genetic analysis. The Company’s products and services serve customers in a range of markets, enabling the adoption of genomic solutions in research and clinical settings. The Company’s customers include genomic research centers, academic institutions, government laboratories and hospitals, as well as pharmaceutical, biotechnology, agrigenomics and commercial molecular diagnostic laboratories, and consumer genomics companies.
To view Vetr’s full report, visit Vetr’s official website.
Receive News & Ratings for Illumina Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina Inc. and related companies with MarketBeat.com's FREE daily email newsletter.